KRASstatus and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KRASstatus and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis
Authors
Keywords
-
Journal
Colorectal Disease
Volume 16, Issue 11, Pages O370-O378
Publisher
Wiley
Online
2014-08-23
DOI
10.1111/codi.12749
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
- (2013) D. P. Modest et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells
- (2013) Giulia M. Stella et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
- (2013) Shuangjie Wu et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines
- (2012) Stefan Heindl et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines
- (2012) Isabelle Messner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study
- (2011) Giuseppe Colucci et al. ONCOLOGY
- BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
- (2010) Chen Mao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- International Trends in Colorectal Cancer Incidence Rates
- (2009) M. M. Center et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
- (2008) F Cappuzzo et al. BRITISH JOURNAL OF CANCER
- Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified
- (2008) J. P T Higgins INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now